About us
Skin conditions have a significant impact on society and people’s quality of life.
There are over three thousand dermatological pathologies. Approximately fifteen million Italian citizens, 25% of the population, suffer from skin diseases. It is estimated that during their lifetime, one in three people will have to deal with some form of dermatological pathology. Diseases such as atopic dermatitis and eczema are increasingly widespread.
In this context, research and diagnostics offer increasingly advanced and sophisticated studies and tools, which must be matched by equally effective therapies.
IDI Farmaceutici is part of the IDI Group, which includes hospitals—including the IRCCS Istituto Dermopatico dell’Immacolata, a center of excellence in the scientific and therapeutic fields—rehabilitation centers, and nursing homes (RSAs).
IDI Farmaceutici constitutes the Group’s industrial hub, and its activities involve pharmaceuticals, medical devices, and dermocosmetics. The company manages all phases of the pharmaceutical cycle in-house: research, applications, production, and marketing.
IDI Farmaceutici is a constantly evolving entity, both in terms of research and investment. This commitment translates into an increase in quality standards and operational capacity, allowing IDI Farmaceutici to produce on behalf of other major Italian pharmaceutical companies and to look toward international markets with confidence.
Science and technology at everyone’s service
Skin diseases cannot be considered minor pathologies, as is sometimes believed. Not only because they include cancerous and infectious phenomena, but also because many dermatological diseases often have a marked and prolonged impact on the lives of those affected. Furthermore, skin problems are sometimes a symptom or manifestation of other pathologies. These considerations guide the work of IDI Farmaceutici in a continuous exchange of experiences between the Group’s various institutes and in the development of a team that makes synergies between dermatology, chemistry, biology, and pharmacology its strength.
Cutting-edge results
The future of dermatological drugs has already begun, and IDI Farmaceutici is at the forefront of the challenge to improve people’s health and quality of life.
The IDI Group can boast significant results in the
research and production of drugs for dermatosis,
dermatitis, psoriasis, acne, and all other major
skin pathologies.
The guiding principle of IDI Farmaceutici is that—affirmed by modern dermatology—aimed at
seeking to treat not
only the symptomatic
manifestations of the
pathology but also
its underlying causes.
In the field of dermocosmetics, IDI Farmaceutici is also committed to the research of increasingly safe and effective products. The studies and applications of an active ingredient such as Niacinamide (or Nicotinamide) follow this direction. The molecule is the basis of many latest-generation IDI Farmaceutici products and, given its effectiveness in skin defense, is an essential component of sunscreens. In this regard, IDI Farmaceutici is personally involved in ‘on-the-ground’ prevention and awareness campaigns to educate people on how to protect themselves from solar rays without putting their skin at risk.
Trade associations
IDI Farmaceutici is part of the most important industry associations,
fully adhering to their codes of ethics.
Unindustria
for territorial development
and labor policies
Farmindustria
for pharmaceuticals and Scientific
Information
Federchimica
regarding
chemical raw materials
Cosmetica Italia
for activities related
to cosmetics and medical devices